We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-21.88%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$397M
AUM Growth
-$118M
Cap. Flow
+$42.4M
Cap. Flow %
10.67%
Top 10 Hldgs %
64.21%
Holding
58
New
7
Increased
4
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$16.7M
2
ZYME icon
Zymeworks
ZYME
+$8.65M
3
SRRK icon
Scholar Rock
SRRK
+$5.8M
4
ALXO icon
ALX Oncology
ALXO
+$4.49M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$4.08M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$4.64M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$518K
3
NKTX icon
Nkarta
NKTX
+$11

Sector Composition

Rank Sector Weight
1 Healthcare 97.57%
2 Financials 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
51
Rocket Pharmaceuticals
RCKT
$394M
$643K 0.16%
40,550
– –
VTGN icon
52
VistaGen Therapeutics
VTGN
$12.8M
$606K 0.15%
16,288
– –
KRON
53
DELISTED
Kronos Bio
KRON
$565K 0.14%
78,131
– –
KLRS
54
Kalaris Therapeutics
KLRS
$96.8M
$556K 0.14%
3,580
– –
NGM
55
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$208K 0.05%
13,669
– –
ATXS
56
DELISTED
Astria Therapeutics
ATXS
$168K 0.04%
25,000
– –
AMRN
57
Amarin Corp
AMRN
$303M
$82K 0.02%
1,250
– –
ALLK
58
CALL
DELISTED
Allakos
ALLK
– –
-168,200
Closed -$1.65M
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2022 Portfolio in Review

As of Q1 2022, Samsara BioCapital held 58 positions worth $397M, down 23% from $515M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Samsara BioCapital deployed $42.4M of net new capital in Q1 2022, opening 7 new positions and adding to 4 existing holdings. Its largest new stake was Arcellx: 999,727 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $4.64M trimmed.

  • Samsara BioCapital's largest Q1 2022 buy was Arcellx: 999,727 shares worth $14M.
  • Samsara BioCapital added most to Centessa Pharmaceuticals in Q1 2022, an estimated $3.87M increase.
  • Samsara BioCapital's biggest Q1 2022 reduction was SpringWorks Therapeutics, cutting an estimated $4.64M.
  • Samsara BioCapital's ten largest holdings make up 64% of its $397M portfolio in Q1 2022.
  • Samsara BioCapital opened 7 new positions and closed 1 in Q1 2022.
  • Samsara BioCapital's portfolio value fell 23% quarter-over-quarter to $397M.

Based on Samsara BioCapital's 13F filing for Q1 2022, filed 16 May 2022.